The capital raise also needs shareholder approval. A capital raise may get approved with some adjustments. Issuing Options may not be part of the deal. If the company is going to increase revenues Options aren't a good idea, more dilutive.
The contingency to adjust the price down may have been due to the possibility of the FDA Approval being delayed. It was expected in March.
Ann: FDA Approval for Xprecia Prime, page-35
Add UBI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
0.005(3.57%) |
Mkt cap ! $43.22M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.5¢ | 13.5¢ | $12.02K | 86.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3650 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 62119 | 3 |
View Market Depth
| Last trade - 15.59pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
14.3¢ |
Change
0.005 ( 5.56 %) |
||||
| Open | High | Low | Volume | ||
| 14.0¢ | 14.3¢ | 13.5¢ | 103859 | ||
| Last updated 15.56pm 17/06/2024 ? | |||||
| UBI (ASX) Chart |
